ZGEN – I thought some of the company’s IFN-lambda slides on today’s CC were disingenuous. The slides in question compared the safety profile of IFN-lambda monotherapy side by side with the safety profile of IFN-alpha plus ribavirin (from separate trials).
>ZGEN – Note that somewhat strangely the PR talks of mean max viral load reductions being 3.6. And that, being a non-standard metric and possibly contaminated by the transient spike down (at day 4), comes across as a little exaggerated.<
Actually, mean max log reduction in viral load (as opposed to mean log reduction at a fixed time point) is a common metric in early-stage HCV trials.
The mean viral load reduction in HCV in the most potent arm (1.5 QW) was 3.6 log (see caveat below).
Note that I believe this is probably on the high side of what will be seen if you tried to replicate it - since I compared the day 8 response for 1.5 QW with day 8 1.5 Q2W. At day 8 the two should be comparible but the QW group is doing substantially better than the Q2W group. That said I still think even if you corrected it by 20% (a WAG pulled from how much worse the Q2W day 8 data was than the QW) it is still well above 2.0.
Market Data 
Markets 
AI
